Trial reportHepatology communications2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Trial report in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04197479 (A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Who cites it
3 citing papers in PubMed.
- Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.International journal of molecular sciences · 2026Review
- The Latest Therapeutic Targets and New Drug Research of Metabolic Dysfunction-Associated Steatotic Liver Disease.Clinical pharmacology and therapeutics · 2026Review
- The dynamic trajectory of circulating exosome components in high-fat diet-induced metabolic-associated steatotic liver disease and its modulation by curcuminoids.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom.
methodsPatients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%).
resultsMAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa <8.5 kPa] treated with 80 mg or 100 mg resmetirom or placebo or 100 mg open-label resmetirom. Baseline HRQL for MASH cirrhosis was significantly lower (up to -15% of score range) for all 6 domains of CLDQ-NAFLD and 13/17 domains of LDQoL (p<0.05). MASH cirrhosis, by week 24 of resmetirom treatment year 1, had improvements in Worry (CLDQ-NAFLD) and Health Distress (LDQoL) up to +4% of score range, sustained through week 52 and throughout year 2 (day 1, week 12, week 28) (p<0.05). Cirrhotic patients with MRI-PDFF response by year 1 week 52, improved in Stigma score (LDQoL): mean change (+3.9 vs. -4.2, p=0.042). Early MASH receiving resmetirom experienced improvement in: Abdominal and Worry (CLDQ-NAFLD) and Health Distress (LDQoL) (up to +5% of score range size); no similar improvements observed in placebo (all p>0.05). Early MASH patients with MRI-PDFF response experienced Abdominal and Worry score (up to +6%) improvements-greater than placebo or nonresponders.
conclusionsEarly MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.